sustain 6 trial semaglutide Summary of the main cardiovascular outcomes of the SUSTAIN-6 Semaglutide, reduction in glycated haemoglobin

Visual inspection alone is insufficient because early-stage degradation from heat exposure often leaves no visible markers until days later

Since GLP-1RA therapy has been shown to reduce preference for fatty foods [26], GLP-1RA therapy might be preferred for patients who would find it difficult to avoid fatty foods under normal circumstances

Triple-Hormone-Receptor Agonist Retatrutide for Obesity PubMed

Eli Lilly became the first healthcare or pharma company to reach a $1 trillion valuation

GHSR-1a selectivity limits HPA axis activation by restricting intracellular signaling cascades primarily to pathways associated with growth hormone exocytosis rather than corticotropin release

Understanding how these preferences evolve could help guide formulation strategies across categories such as functional beverages, protein products and nutritional foods, where nutrient density and satiety are increasingly valued